Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPID-engineered GIPR antagonist antibody
- Development stage
- Preclinical
- Lead developer
- PROTEINA
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
SPID-engineered GIPR antagonist antibody is a long-acting monoclonal antibody developed by PROTEINA Co., Ltd. for the treatment of obesity and metabolic disorders. Engineered using the SPID (Surface-displayed Protein Interaction Design) platform and deep mutational scanning (DMS), the antibody is optimized for high affinity, pH-sensitive recycling, and metabolic durability. In preclinical studies using diet-induced obesity (DIO) models, the lead candidate demonstrated a 47-day half-life and superior weight loss and glycemic control compared to earlier iterations. The drug is designed to serve as a maintenance-oriented monotherapy or a foundational backbone for next-generation combination regimens in chronic weight management.
- Other names
- SPID-Engineered Long-Acting GIPR Antagonist Antibody
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on SPID-engineered GIPR antagonist antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPID-engineered GIPR antagonist antibody.